Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
Christopher Bowlus, MD
Modality
protein_peptide
Development Phase
Phase 4 / Approved
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
51Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02078882CT.gov Study of Abatacept (Orencia) to Treat Primary Biliary Cirrhosis | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Primary Biliary Cholangitis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Abatacept Recombinant (this asset) | Christopher Bowlus, MD | Approved | BB · 66 |
| Ursodeoxycholic Acid | Xijing Hospital of Digestive Diseases | P4 | A |
| Fenofibrate | Xijing Hospital of Digestive Diseases | P3 | BB |
| Saroglitazar | Zydus Therapeutics Inc. | P3 | BB |
| cs0159 | Cascade Pharmaceuticals, Inc | P3 | BB |
| Seladelpar | Gilead Sciences | P3 | BB |
| Obeticholic Acid | Intercept Pharmaceuticals | P3 | BB |
| 2-(P-(2-(P-CHLOROBENZAMIDO)ETHYL)PHENOXY)-2-METHYLPROPIONIC ACID | Intercept Pharmaceuticals | P3 | BB |
| Rituximab | Newcastle-upon-Tyne Hospitals NHS Trust | P2 | BB |
+41 more in the Primary Biliary Cholangitis cohort
Other indications for Abatacept Recombinant
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Lymphoblastic Leukemia | — | P3 | BB · 68 |
| Acute Biphenotypic Leukemia | — | P3 | B · 63 |
| Acute Myeloid Leukemia | — | P3 | B · 60 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Abatacept Recombinant in Primary Biliary Cholangitis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/abatacept-recombinant-primary-biliary-cholangitis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →